Netherlands · Delayed Price · Currency is EUR Vivoryon Therapeutics Statistics
Total Valuation
AMS:VVY has a market cap or net worth of EUR 37.25 million. The enterprise value is 27.97 million.
| Market Cap | 37.25M |
| Enterprise Value | 27.97M |
Important Dates
The next estimated earnings date is Tuesday, September 9, 2025.
| Earnings Date | Sep 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AMS:VVY has 26.23 million shares outstanding. The number of shares has increased by 3.27% in one year.
| Current Share Class | 26.23M |
| Shares Outstanding | 26.23M |
| Shares Change (YoY) | +3.27% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.87% |
| Owned by Institutions (%) | 20.15% |
| Float | 21.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.73 |
| P/TBV Ratio | 5.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.36 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.46 |
Financial Position
The company has a current ratio of 7.20, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.20 |
| Quick Ratio | 6.93 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -445.98 |
Financial Efficiency
Return on equity (ROE) is -120.41% and return on invested capital (ROIC) is -76.38%.
| Return on Equity (ROE) | -120.41% |
| Return on Assets (ROA) | -62.22% |
| Return on Invested Capital (ROIC) | -76.38% |
| Return on Capital Employed (ROCE) | -212.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.47M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.40% in the last 52 weeks. The beta is 1.96, so AMS:VVY's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | -36.40% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 38.76 |
| Average Volume (20 Days) | 43,928 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.96M |
| Pretax Income | -20.57M |
| Net Income | -20.57M |
| EBITDA | -20.87M |
| EBIT | -20.96M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
The company has 9.39 million in cash and 102,000 in debt, giving a net cash position of 9.28 million or 0.35 per share.
| Cash & Cash Equivalents | 9.39M |
| Total Debt | 102,000 |
| Net Cash | 9.28M |
| Net Cash Per Share | 0.35 |
| Equity (Book Value) | 7.88M |
| Book Value Per Share | 0.30 |
| Working Capital | 8.67M |
Cash Flow
In the last 12 months, operating cash flow was -19.17 million and capital expenditures -2,000, giving a free cash flow of -19.18 million.
| Operating Cash Flow | -19.17M |
| Capital Expenditures | -2,000 |
| Free Cash Flow | -19.18M |
| FCF Per Share | -0.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AMS:VVY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.27% |
| Shareholder Yield | n/a |
| Earnings Yield | -55.21% |
| FCF Yield | -51.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |